RGNX vs ZVRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZVRA Captures Institutional Edge (3โ1 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zevra Therapeutics, Inc. Common Stock (ZVRA) driven by superior Valuation, Growth & Margin, Momentum & Technical while RGNX counters with relative strength in Options & Structure. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus ZVRA at 9.3x Forward P/E and 31.5% operating margin (+44.9% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against ZVRA sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RGNX Revenue | ZVRA Revenue | RGNX Op. Margin | ZVRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $220M | N/A | 40.3% | N/A | RGNX |
| FY2019 | $40M | $10M | -422.9% | -158.4% | ZVRA |
| FY2020 | $150M | $10M | -77.1% | -42.2% | ZVRA |
| FY2021 | $470M | $30M | 34.0% | 27.0% | RGNX |
| FY2022 | $110M | $10M | -233.2% | -418.9% | RGNX |
| FY2023 | $90M | $30M | -297.1% | -180.6% | ZVRA |
| FY2024 | $80M | $20M | -280.0% | -368.5% | RGNX |
| FY2025 | $170M | $110M | -94.6% | -59.1% | ZVRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RGNX | ZVRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $500.9M | $664.1M | Larger Scale | ZVRA |
| Trailing P/E Ratio Valuation | N/M | 9.7x | Lower Multiple | ZVRA |
| Forward P/E Ratio Valuation | N/M | 9.3x | Lower Multiple | ZVRA |
| Revenue Growth (YoY) Growth | -69.2% | +44.9% | Higher Growth | ZVRA |
| Operating Margin (TTM) Profitability | -120.4% | 31.5% | Higher Margin | ZVRA |
| Net Profit Margin Profitability | -113.9% | 52.8% | Higher Margin | ZVRA |
| Return on Equity (ROE) Capital Efficiency | -113.2% | 41.9% | Higher ROE | ZVRA |
| 52-Week Range Position Momentum | 19% ($5โ$16) | 18% ($8โ$15) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 1.81ฮฒ ยท 76% Vol | 1.18ฮฒ ยท 95% Vol | Lower Realized Risk | RGNX |
| Unified Institutional Score Composite Signal | 45.3 / 100 (HOLD) | 49.4 / 100 (HOLD) | Higher Composite | ZVRA |